Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4175185 | 1.00 | CHRM5 (0.33) | CHRM5ADRA2CCYP1A2CYP2D6MEN1 | |
| SCHEMBL7593004 | 0.97 | CYP2D6 (0.32) | CYP2D6MEN1KMT2ALMNASLC18A3 | |
| SCHEMBL13836053 | 0.94 | CYP2D6 (0.33) | CHRM5ADRA2CCYP2D6MEN1KMT2A | |
| SCHEMBL13835555 | 0.92 | CYP2D6 (0.34) | CHRM5ADRA2CCYP1A2CYP2D6MEN1 | |
| SCHEMBL27729 | 0.91 | — | — | |
| SCHEMBL29941024 | 0.91 | CYP2D6 (0.31) | CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL3399160 | 0.89 | — | — | |
| SCHEMBL875158 | 0.88 | CHRNA7 (0.32) | — | |
| SCHEMBL24409361 | 0.86 | — | — | |
| SCHEMBL28564 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10619058-B2 | Curable composition | TOAGOSEI CO., LTD. (JP) | 2020-04-14 | — | — | US | disclosed |
| US-10611856-B2 | Curable composition | TOAGOSEI CO., LTD. (JP) | 2020-04-07 | — | — | US | disclosed |
| EP-3133058-B1 | MULTIFUNCTIONAL (METH)ACRYLATE MANUFACTURING METHOD | TOAGOSEI CO LTD (JP) | 2019-05-29 | — | — | EP | disclosed |
| US-20180237629-A1 | CURABLE COMPOSITION | TOAGOSEI CO., LTD. (JP) | 2018-08-23 | — | — | US | disclosed |
| US-10035752-B2 | Multifunctional (meth)acrylate manufacturing method | TOAGOSEI CO., LTD. (JP) | 2018-07-31 | — | — | US | disclosed |
| US-20180187026-A1 | CURABLE COMPOSITION | TOAGOSEI CO., LTD. (JP) | 2018-07-05 | — | — | US | disclosed |
| US-20180171038-A1 | CURABLE COMPOSITION | TOAGOSEI CO., LTD. (JP) | 2018-06-21 | — | — | US | disclosed |
| US-20170204044-A1 | MULTIFUNCTIONAL (METH)ACRYLATE MANUFACTURING METHOD | TOAGOSEI CO., LTD. (JP) | 2017-07-20 | — | — | US | disclosed |
| EP-3133058-A1 | MULTIFUNCTIONAL (METH)ACRYLATE MANUFACTURING METHOD | Toagosei Co., Ltd. (JP) | 2017-02-22 | — | — | EP | disclosed |
| EP-2880033-A1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | Purdue Pharma LP (US) | 2015-06-10 | — | — | EP | disclosed |
| WO-2012085648-A9 | PHOSPHORUS-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA L.P. (US) | 2013-03-21 | — | — | WO | disclosed |
| EP-2554243-A1 | ACIDIC GAS ABSORBENT, ACIDIC GAS REMOVAL DEVICE, AND ACIDIC GAS REMOVAL METHOD | Kabushiki Kaisha Toshiba (JP) | 2013-02-06 | — | — | EP | disclosed |
| US-20120294785-A1 | ACIDIC GAS ABSORBENT, ACIDIC GAS REMOVAL DEVICE, AND ACIDIC GAS REMOVAL METHOD | KABUSHIKI KAISHA TOSHIBA (JP) | 2012-11-22 | — | — | US | disclosed |
| WO-2012158844-A1 | HETEROCYCLIC COMPOUNDS | SHIONOGI & CO., LTD. (JP) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012085648-A1 | PHOSPHORUS-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA L.P. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2011162409-A1 | COMPOUNDS HAVING TRPV1 ANTAGONISTIC ACTIVITY AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2011-12-29 | — | — | WO | disclosed |
| EP-2142529-A2 | TRPV1 ANTAGONISTS AND USES THEREOF | Purdue Pharma LP (US) | 2010-01-13 | — | — | EP | disclosed |
| EP-2076506-A2 | HETEROCYCLIC-SUBSTITUTED PIPERIDINES AS ORL-1 LIGANDS | Purdue Pharma L.P. (US) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008132600-A2 | TRPV1 ANTAGONISTS AND USES THEREOF | PURDUE PHARMA L.P. (DE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008089201-A2 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE AS ORL-1 LIGANDS | PURDUE PHARMA L.P. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180171038-A1 | CURABLE COMPOSITION | KAT2B, ACR, GK | CHRM5 1270/4885ADRA2C 3420/4885CYP1A2 4499/4885 |
| US-20180187026-A1 | CURABLE COMPOSITION | AZI2, KAT2A, KAT2B | CHRM5 891/4885ADRA2C 2932/4885CYP1A2 3833/4885 |
| US-10035752-B2 | Multifunctional (meth)acrylate manufacturing method | MMAB, AMD1, ADH5 | CHRM5 1379/4885ADRA2C 4035/4885CYP1A2 609/4885 |
| US-10611856-B2 | Curable composition | ACR, KAT2B, KAT5 | CHRM5 1226/4885ADRA2C 3522/4885CYP1A2 4521/4885 |
| US-20170204044-A1 | MULTIFUNCTIONAL (METH)ACRYLATE MANUFACTURING METHOD | MMAB, AMD1, ADH5 | CHRM5 1379/4885ADRA2C 4035/4885CYP1A2 609/4885 |
| US-10619058-B2 | Curable composition | ZMYND8, AZI2, KAT2A | CHRM5 1231/4885ADRA2C 3274/4885CYP1A2 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.